Evidence map›Paper›PMID 40165291›Full record

ReviewStem cell research & therapy2025

A perfect islet: reviewing recent protocol developments and proposing strategies for stem cell derived functional pancreatic islets.

Sujitha Sali, Leen Azzam, Taraf Jaro, Ahmed Ali Gebril Ali, Ali Mardini, Omar Al-Dajani, Shahryar Khattak, Alexandra E Butler, Juberiya M Azeez, Manjula Nandakumar

Abstract readReview
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sujitha Sali *King Abdullah University of Science and Technology (KAUST), Thuwal, 23955, Saudi Arabia.
Leen Azzam *School of Medicine, Royal College of Surgeons in Ireland Bahrain, Busaiteen, 15503, Bahrain.
Taraf JaroSchool of Medicine, Royal College of Surgeons in Ireland Bahrain, Busaiteen, 15503, Bahrain.
Ahmed Ali Gebril AliSchool of Medicine, Royal College of Surgeons in Ireland Bahrain, Busaiteen, 15503, Bahrain.
Ali MardiniSchool of Medicine, Royal College of Surgeons in Ireland Bahrain, Busaiteen, 15503, Bahrain.
Omar Al-DajaniSchool of Medicine, Royal College of Surgeons in Ireland Bahrain, Busaiteen, 15503, Bahrain.
Shahryar KhattakKing Abdullah University of Science and Technology (KAUST), Thuwal, 23955, Saudi Arabia.
Alexandra E ButlerResearch Department, School of Postgraduate Studies & Research, Royal College of Surgeons in Ireland Bahrain, Adliya, 15503, Bahrain. aeb91011@gmail.com.ORCID http://orcid.org/0000-0002-5762-3917
Juberiya M Azeez *Research Department, School of Postgraduate Studies & Research, Royal College of Surgeons in Ireland Bahrain, Adliya, 15503, Bahrain.
Manjula Nandakumar *Research Department, School of Postgraduate Studies & Research, Royal College of Surgeons in Ireland Bahrain, Adliya, 15503, Bahrain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for an effective cell replacement therapy for diabetes has driven the development of "perfect" pancreatic islets from human pluripotent stem cells (hPSCs). These hPSC-derived pancreatic islet-like β cells can overcome the limitations for disease modelling, drug development and transplantation therapies in diabetes. Nevertheless, challenges remain in generating fully functional and mature β cells from hPSCs. This review underscores the significant efforts made by researchers to optimize various differentiation protocols aimed at enhancing the efficiency and quality of hPSC-derived pancreatic islets and proposes methods for their improvement. By emulating the natural developmental processes of pancreatic embryogenesis, specific growth factors, signaling molecules and culture conditions are employed to guide hPSCs towards the formation of mature β cells capable of secreting insulin in response to glucose. However, the efficiency of these protocols varies greatly among different human embryonic stem cell (hESC) and induced pluripotent stem cell (hiPSC) lines. This variability poses a particular challenge for generating patient-specific β cells. Despite recent advancements, the ultimate goal remains to develop a highly efficient directed differentiation protocol that is applicable across all genetic backgrounds of hPSCs. Although progress has been made, further research is required to optimize the protocols and characterization methods that could ensure the safety and efficacy of hPSC-derived pancreatic islets before they can be utilized in clinical settings.

Indexed as

Induced Pluripotent Stem CellsInsulin-Secreting CellsIslets of LangerhansPluripotent Stem CellsAnimalsCell DifferentiationHumansDifferentiation protocolsHuman induced pluripotencyMature Β cellsPancreatic isletStem cells

Identifiers

PMID40165291
PMCPMC11959787

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.